生命科学资讯
生物技术与制药领域的最新动态
Is Illumina’s (ILMN) TruPath Rare Disease Push Reframing Its Clinical Sequencing Investment Narrative? - simplywall.st
Lonza Group AG: Quiet Rally In Swiss Biotech That U.S. Investors Are Missing - AD HOC NEWS
Cardiogenetic testing at scale: the TruGenome Cardiovascular Disease Test and CardioSeq Clinical Trial - Illumina
安捷伦科技在逆风中展现稳健增长势头 - TipRanks
Agilent Technologies Signals Steady Growth Amid Headwinds - TipRanks
安捷伦股价暴跌2.64%，交易量降至4.1亿美元，日交易活跃度排名第322位，财报不及预期但财报后现反弹行情——Bitget
Agilent's Stock Plummets 2.64% as Trading Volume Dips to $0.41B, Ranking 322 in Daily Trading Activity Amid Earnings Miss and Post-Earnings Rally - Bitget
美国卫生与公众服务部禁用Claude AI工具，特朗普寻求全面禁止政府使用Anthropic技术。
HHS bans Claude AI tool as Trump seeks full government blacklisting of Anthropic
摩根士丹利下调安捷伦目标股价，因估值倍数过高 - Investing.com
Morgan Stanley cuts Agilent stock price target on valuation multiples - Investing.com
沃特世公司（WAT）投资者展望：评估潜在24.63%上涨空间——DirectorsTalk访谈
Waters Corporation (WAT) Investor Outlook: Evaluating A Potential 24.63% Upside - DirectorsTalk Interviews
赛默飞世尔（NYSE: TMO）人力资源主管为缴纳税款处置股份 - 股票泰坦
Thermo Fisher (NYSE: TMO) HR chief disposes shares to cover tax liability - Stock Titan
10x Genomics (TXG) CEO Serge Saxonov获重大限制性股票单位奖励 - 股票泰坦
Major RSU grant to 10x Genomics (TXG) CEO Serge Saxonov - Stock Titan
ACIP三月会议前再添两名新成员
Two more members added to ACIP ahead of March meeting
深入剖析10x Genomics：11位分析师分享观点 - Benzinga
Breaking Down 10x Genomics: 11 Analysts Share Their Views - Benzinga
Cullgen放弃与Pulmatrix的反向合并，选择以3亿美元收购Gyre。
Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout
TCE生物科技Candid通过反向并购罕见病专注企业Rallybio登陆纳斯达克。
TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio
勃林格殷格翰终止与OSE的MASH协议，生物科技公司持续精简研发管线。
Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline
Thermo Fisher Scientific：生命科学解决方案业务复苏（纽交所代码：TMO）- Seeking Alpha
Thermo Fisher Scientific: Recovery In Life Sciences Solutions (NYSE:TMO) - Seeking Alpha
评估安捷伦科技(A)近期股价疲软与长期收益后的估值 - 雅虎财经
Assessing Agilent Technologies (A) Valuation After Recent Share Price Softness and Long Term Gains - Yahoo Finance
Ascendis获FDA批准侏儒症新药上市
Ascendis wins FDA approval of dwarfism drug
Illumina公司（ILMN）3月2日交易下跌2.84% - GuruFocus
Illumina Inc (ILMN) Trading Down 2.84% on Mar 2 - GuruFocus